Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Self-administered injectable contraceptives, which are progestin-only shots taken at home every three months, have been ...
Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.
A study reveals that many clinicians remain unaware of self-administered injectable contraception, despite its decades-long ...
A fear of needles in a medical setting (often called trypanophobia when it’s more severe) is common and can make TRT ...
Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback